BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NextPharma Technologies Announces Change in CEO Leadership


9/23/2011 10:43:40 AM

Surrey, UK, 23rd September 2011 – NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotech industry, today announced that Bill Wedlake, NextPharma?s Chief Executive Officer will step down effective 30th September, 2011. Franck Latrille, NextPharma?s new CEO, replaces Bill and will take up his position on Monday 3rd October, 2011.

Bill Wedlake joined NextPharma in July 2000 as Chief Financial Officer in the same year that it was founded. In 2003 he was appointed Chief Executive Officer and joined the Board of Directors. Bill who has contributed significantly to the growth and development of the NextPharma business is working closely with Franck to ensure a smooth transition process. The rest of the NextPharma executive management team remains unchanged.

David Finnigan of Sun European Partners, NextPharma?s shareholder commented “I am very grateful to Bill for his considerable contributions to NextPharma over the past eleven years and I wish him every success for the future”. Finnigan continued “NextPharma is in a tremendous position to extend its share of the outsourcing market and its Board of Directors is pleased to be able to appoint an executive with Frank?s experience and track record to lead NextPharma to its next stage of growth and development.

Franck Latrille joins NextPharma with a broad and deep experience of the global pharmaceutical industry, having most recently held executive board positions at Merck-Serono SA, including Deputy CEO and EVP Marketing and Sales. Previously at Serono SA he held executive board positions with responsibility for pharmaceutical manufacturing and product development operations. He holds a PhD in biochemistry and physiology.

NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers from tablets and capsules to antibiotics, hormones, steriles and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing, with particular expertise in product development and manufacture of oncology medicines.

NextPharma has recently been acquired by Sun European Partners with a view to leveraging NextPharma?s strong track record, reputation and state of the art facilities, to grow the business both organically and by acquisition.

NextPharma Technologies Holding Limited

Tel +44 (0) 1483 479 120

About NextPharma

NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry.

NextPharma offers a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing for New Chemical Entities (NCEs)/New Biological Entities (NBEs) and generic products. The company is a world leader in lyophilization, sterile fill finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled drugs. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules. Additionally NextPharma has significant expertise in paediatric drug formulation, development and manufacture. NextPharma offers „one-stop? logistics solutions tailored to meet the needs of the global pharmaceutical industry under the rigid standards of cGSP/GDP regulations.

NextPharma operates globally with seven product development centers, seven manufacturing plants and six temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan.

NextPharma has 1,200 employees dedicated to serving over 200 customers worldwide and a customer base, which includes many of the world?s leading pharmaceutical, specialty pharma and biotech companies.

NextPharma has a proven track record in almost all pharmaceutical technologies and 3 product forms and in addition to the specialist areas above have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies.

All of its sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES